Abstract
The initial discovery that a compound possesses antiarrhythmic activity is usually made in simple screening models involving the use of arrhythmogenic chemicals like aconitine, chloroform or ouabain. If promising results are obtained in these tests then the potential antiarrhythmic drug may be tested (usually in conscious dogs) for its ability to suppress ventricular ectopic activity ensuing 1–2 days after the production of myocardial ischaemia. Historically this sequence of events holds especially for the group of drugs variously described as ‘membrane stabilisers’, ‘sodium channel blockers’ or ‘class 1 agents’ (Vaughan Williams, 1970). Consequently, there is comparatively little literature describing the effects of sodium channel blocking agents on the early experimental ventricular arrhythmias and fibrillation which occur within minutes of the onset of myocardial ischaemia. The reasons for this are many but surely include the difficulties involved in producing a consistent quantitative model in which to assess the protective actions of putative antiarrhythmic drugs. For instance, our own experiences have shown that one-stage coronary artery ligation does not produce ventricular ectopic activity in every species — rabbits and guineapigs being particularly resistant. In addition even in those species which demonstrate early ventricular arrhythmias (for example, the dog), ligation of the same coronary artery can be associated with a range of incidence of ventricular fibrillation (VF) of between zero and 100 per cent depending on the laboratory (see Stephenson et al., 1960, for review of early literature, and chapter 6 of this book).
Keywords
- Ventricular Arrhythmia
- Left Anterior Descend
- Antiarrhythmic Drug
- Action Potential Duration
- Antiarrhythmic Agent
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Adgey, A. A. J., Allen, J. D., Geddes, J. S., James, R. G., Webb, G., Zaidi, S. W. and Pantridge, J. F. (1971). Acute phase of myocardial infarction. Lancet, ii, 510–4
Aldor, E. and Heeger, H. (1976). Propafenone ein neues Antarrhythmikum. Dt. med. Wschr., 101, 1318–22
Allen, J. D., James, R. G. G., Kelly, J. G., Shanks, R. G. and Zaidi, S. A. (1977). Comparison of the effects of lignocaine and mexiletine on experimental ventricular arrhythmias. Postgrad. med. J., 53, 35–45
Allen, J. D., Kofi Ekue, J. M., Shanks, R. G. and Zaidi, S. A. (1970). The effect on experimental cardiac arrhythmias of a new anticonvulsant agent, Kö 1173, and its comparison with phenytoin and procainamide. Br. J. Phaemac., 39, 183–4P
Allen, J. D., Kofi Ekue, J. M., Shanks, R. G. and Zaidi, S. A. (1972). The effect of Kö 1173, a new anticonvulsant agent on experimental cardiac arrhythmias. Br. J. Pharmac., 45, 561–73
Anderson, J. L., Mason, J. W., Winkle, R. A., Meffin, P. J., Fowles, R. E., Peters, F. and Harrison, D. C. (1978). Clinical electrophysiological effects of tocainide. Am. J. Cardiol., 41, 415
Ankier, S. I., Carmichael, D. J. S. and Kidner, P. H. (1977). Disopyramide — a review. Scot. med. J., 22, 314–9
Arita, M., Goto, M., Nagamoto, Y. and Saikawa, T. (1979). Electrophysiological actions of mexiletine (Kö 1173) on canine Purkinje fibres and ventricular muscle. Br. J. Pharmac., 67, 143–52
Arnsdorf, M. F. (1976). Electrophysiologic properties of antidysrhythmic drugs as a rational basis for therapy. Med. Clin. N. Am., 60, 213–32
Arnsdorf, M. F. and Bigger, J. T. (1972). Effect of lidocaine hydrochloride on membrane conductance in mammalian cardiac Purkinje fibres. J. clin. Invest., 51, 2252–63
Au, T. L. S., Collins, G. A., MacLeod, B. A. and Walker, M. J. A. (1979a). Arrhythmic responses to coronary occlusion in different species. Proc. Can. Fedn. biol. Soc., 22, 63
Au, T. L. S., Collins, G. A., Harvie, C. J. and Walker, M. J. A. (1979b). The actions of prostaglandins I2 and E2 on arrhythmias produced by coronary occlusion in the rat and dog. Prostaglandins, 18, 707–20
Bagwell, E. E., Walle, T., Drayer, D. E., Reidenberg, M. M. and Pruett, J. K., (1976). Correlation of the electrophysiological and antiarrhythmic properties of the N-acetyl metabolite of procainamide with plasma and tissue drug concentrations in the dog. J. Pharmac. exp. ther., 197, 38–48
Bar, F., Forré, J., Gorgels, A. and Wellens, H. (1978). Electrophysiological effects of lorcainide, a new antiarrhythmic drug in man. Circulation, 58, 966
Beck, O. A. and Hochrein, H. (1978). Wirksamkeit und Risiken von Propafenon bei der Akutbehandlung von Herzrhythmusstoerungen. Dt. med. Wschr., 103, 1261–5
Beck, O. A., Witt, E. and Hochrein, H. (1975). Antiarrhythmikmus Propafenon auf die intrakardiale Erregungsleitung. Klinische Untersuchungen mit Hilfe der His-Buendel-Elektrographie. Z. Kardiol., 64, 179–87
Benett, M. A., Wilner, J. M. and Pentecost, B. L. (1970). Controlled trial of lignocaine prophylaxis of ventricular arrhythmias complicating myocardial infarction. Lancet, ii, 909–11
Bigger, J. T. and Heissenbuttel, R. H. (1969). The use of procainamide and lidocaine in the treatment of cardiac arrhythmias. Progr. cardiovasc. Dis., 11, 515–34
Bigger, J. T. and Mandel, W. J. (1970). Effect of lidocaine on the electrophysiological properties of ventricular muscle and Purkinje fibres. J. clin. Invest., 49, 63–77
Blanke, H., Aschbrenner, B., Karsch, K. R. and Kreuger, H. (1979). Plasmaspiegel-Wirkungs-Beziehung und Organverteilung von Propafenon. Dt. med. Wschr., 104, 587–91
Bleifeld, W., Merx, W., Heinrich, K. W. and Effert, S. (1972). Lidocain zur Arrhythmieprophylaxe beim frischen Infarkt. Verh. dt. Ges. inn. Med., 78, 1035–9
Borer, J. S., Harrison, L. A., Kent, K. M., Levy, R., Goldstein, R. E. and Epstein, S. E. (1976). Beneficial effect of lidocaine on ventricular electrical stability and spontaneous ventricular fibrillation during experimental myocardial infarction. Am. J. Cardiol., 37, 860–3
Biissmann, W. D., Schreiber, S. and Kaltenbach, M. (1980). Comparison of antiarrhythmic effects of oral prajmalium bitartrate and intravenous lidocaine in acute myocardial infarction. Am. Heart. J., 99, 589–97
Byrne, J. E., Gomoll, A. W. and McKinney, G. R. (1977). Antiarrhythmic properties of MJ 9067 in acute animal models. J. Pharmac. exp. Ther., 200, 147–54
Cabedo, J. A. F., Insa Perez, L. D., Merino, V. L., Salana, S. B., Auban, A. B. and Requena, J. E. (1978). Electrophysiological effects of aprindine on A-V conduction in the dog. Arch. int. Pharmacodyn. Thér., 236, 154–63
Campbell, N. P. S., Chaturverdi, N. C., Kelly, J. G., Strong, J. E., Shanks, R. G. and Pantridge, J. F. (1973). Mexiletine (Kö 1173) in the management of dysrhythmias. Lancet, ii, 404–7
Campbell, R. W. F., Pottage, A., Murray, A., Achuff, S. C., Prescott, L. F. and Julian, D. G. (1978). Prophylactic mexiletine therapy in acute myocardial infarction. In Management of Ventricular Tachycardia — Role of Mexiletine (ed. E. Sandoe, D. G. Julian and J. W. Bell), Excerpta Medica, Amsterdam, pp. 479–83
Caracta, A. R. and Damato, A. N. (1975). Procainamide. In Drugs in Cardiology, Vol. 1 (ed. E. Donoso), Stratton Intercontinental, New York, pp. 1–16
Cardinal, R., Janse, M. J., d’Alnoncourt, C. N. and Durrer, D. (1980). Effects of lidocaine on ventricular potentials, activation and arrhythmias during coronary occlusion in the porcine heart. Circulation, 62, Suppl. III, 345
Carmeleit, E. (1979). Electrophysiological evaluation of Org 6001 in isolated tissues. Report to Organon International, 9 July 1979
Carmeliet, E. (1980). Electrophysiological effects of encainide on isolated cardiac muscle and Purkinje fibres and on the Langendorff-perfused guinea-pig heart. Eur. J. Pharmac., 61, 247–62
Carmeliet, E. and Verdonk, F. (1974). Effects of aprindine and lidocaine on transmembrane potentials and radioactive K+ efflux in different cardiac tissues. Acta cardiol., Suppl. 18, 73–90
Carmeliet, E. and Zaman, M. Y. (1979). Comparative effects of lignocaine and lorcainide on conduction in the Langendorff-perfused guinea-pig heart. Cardiovasc. Res., 13, 439–49
Carmeliet, E., Janssen, P. A. J., Marsboom, R., Van Nueten, J. M. and Xhonneux, R. (1978). Antiarrhythmic, electrophysiologic and haemodynamic effects of lorcainide. Arch. int. Pharmacodyn. Thér., 231, 104–30
Chen, C. M., Gettes, L. S. and Katzung, B. G. (1975). Effects of lidocaine and quinidine on steady-state characteristics and recovery kinetics of (d V/dt max) in guinea-pig ventricular myocardium. Circulation Res., 37, 20–9
Clark, C., Foreman, M. I., Kane, K. A., McDonald, F. M. and Parratt, J. R. (1980). Coronary artery ligation of anaesthetised rats as a method for the production of experimental dysrhythmias and for the determination of infarct size. J. pharmac. Meth., 3, 357–68
Cocco, G. and Strozzi, C. (1978). Initial clinical experience of lorcainide (Ro 13–1042), a new antiarrhythmic agent. Eur. J. clin. Pharmac., 14, 105–9
Collett, J. T., Chew, C. Y. C., Campbell, C., Eng, C. and Singh, B. N. (1980). Abolition of early ischaemic ventricular arrhythmias in conscious dogs pretreated with amiodarone. Clin. Res., 28, 161A
Coltart, D. J., Berndt, T. B., Kernoff, R. and Harrison, D. C. (1974). Antiarrhythmic and circulatory effects of Astra W36095, a new lidocaine-like agent. Am. J. Cardiol., 34, 35–41
Conn, R. D. (1965). Diphenylhydantoin sodium in cardiac arrhythmias. New Engl. J. Med., 272, 277–82
Corr, P. B., Helke, C. J. and Gillis, R. A. (1978). Exacerbation of coronary occlusioninduced ventricular arrhythmias by the vagolytic effect of procainamide. Cardiovasc. Res., 8, 486–92
Cosnier, D., Grimal, J. and Duchene-Marullaz, P. (1971). Comparaison des effets du disopyramide, de la dihydroquinidine et du procainamide sur deux types d’arhythmies ventriculaires. Thérapie, 26, 97–107
Cranefield, P. F., Wit, A. L. and Hoffman, B. F. (1972). Conduction of the cardiac impulse. III. Characteristics of very slow conduction. J. gen. Physiol., 59, 227–46
d’Alnoncourt, N. C., Cardinal, R., Janse, M. J., Luederitz, B. and Durrer, D. (1980). Effects of tocainide on ectopic impulse formation in isolated cardiac tissue. Klin. Wschr., 58, 227–31
Dangman, K. H. and Hoffman, B. F. (1978). Effects of N-acetylprocainamide on cardiac Purkinje fibres. Pharmacologist, 20, 150
Danilo, P. R. and Rosen, M. R. (1976). Cardiac effects of disopyramide. Am. Heart J., 92, 532–6
Danilo, P., Hordof, A. J. and Rosen, M. R. (1977a). Effects of disopyramide on electrophysiologic properties of canine cardiac Purkinje fibres. J. Pharmac. exp. Ther., 201, 701–10
Danilo, P., Langan, W. B., Rosen, M. R. and Hoffman, B. F. (1977b). Effects of the phenothiazine analog EN-313 on ventricular arrhythmias in the dog. Eur. J. Pharmac., 45, 127–39
Dean, R. R. (1975). The pharmacology of Norpace. Angiology, 26, Suppl. 1, Pt 2, 67–84
Dean, R. R., McDermott, D. J. and Smith, W. S. (1979). Disopyramide. In Pharmacological and Biochemical Properties of Drug Substances (ed. M. E. Goldberg), American Pharmaceutical Association, New York, pp. 165–85
DiBianco, R., Gottdiener, J. S., Fletcher, R. D., Singh, S., Katz, R. J. and Sauerbrunn, B. (1980). Effects of encainide on left ventricular function; assessment with treadmill exercise and radionuclide ventriculography. Circulation, 62, Suppl. III, 282
Duff, H. J., Roden, D. M. and Woosley, R. L. (1980). Abolition of resistant ventricular arrhythmias by twice daily dosing with flecainide. Circulation, 62, Suppl. III, 181
Dughman, S. and Cohn, K. (1973). Detrimental effect of non-homogeneous distribution of lidocaine to the myocardium. Circulation, 43, Suppl. IV, 132
Elharrar, V. and Zipes, D. P. (1977). Cardiac electrophysiologic alterations during myocardial ischemia. Am. J. Physiol., 233, H329–45
Elharrar, V., Gaum, W. E. and Zipes, D. P. (1977). Effect of drugs on conduction delay and incidence of ventricular arrhythmias induced by acute coronary occlusion in dogs. Am. J. Cardiol., 39, 544–9
El-Sherif, N. and Lazzara, R. (1979). Re-entrant ventricular arrhythmias in the late myocardial infarction period. 7. Effect of verapamil and D600 and the role of the slow channel. Circulation, 60, 605–15
Esser, H. and Kikis, D. (1978). Mexiletine in the suppression of ventricular ectopic activity: short and long term treatment. In Management of Ventricular Tachycardia — Role of Mexiletine (ed. E. Sandoe, D. G. Julain and J. W. Bell), Excerpta Medica, Amsterdam, pp. 585–93
Evans, D. E. and Gillis, R. A. (1974). Effect of diphenylhydantoin and lidocaine on cardiac arrhythmias induced by hypothalamic stimulation. J. Pharmac. exp. Ther., 191, 506–14
Fox, S., Hoffman, B., Rosen, M. and Hoffman, B. (1980). Effects of ethomozine and lidocaine on ventricular fibrillation and defibrillation in anaesthetised dogs. Am. J. Cardiol., 45, 474
Gamble, O. W. and Cohn, K. (1972). Effect of propranolol, procainamide and lidocaine on ventricular automaticity and re-entry in experimental myocardial infarction. Circulation, 46, 498–506
Geddes, J. S., Webb, S. and Pantridge, J. F. (1972). Limitations of lignocaine in control of early ventricular dysrhythmias complicating acute myocardial infarction. Br. Heart J., 34, 964–5
Geltman, E. M., Campbell, M. K., Ambos, H. D. and Roberts, R. (1978). Treatment of refractory ventricular arrhythmias with oral aprindine. Clin. Res., 26, 233A
Georges, A., Horslet, A. and Duvernay, G. (1973). Pharmacological evaluation of aprindine (AC 1802) a new antiarrhythmic agent. Acta cardiol., 28, 166–91
Gerin, M. G. and Kulbertus, H. E. (1978). Effects of various antiarrhythmic agents on conduction delay and incidence of ventricular arrhythmias induced by acute coronary occlusion in the dog. In Management of Ventricular Tachycardia — Role of Mexiletine (ed. E. Sandoe, D. G. Julian and J. W. Bell), Excerpta Medica, Amsterdam, pp. 299–304
Giardina, E. G. and Bigger, J. T. (1973). Procainamide against re-entrant ventricular arrhythmias: lengthening of R-V intervals of coupled ventricular premature depolarization as an insight into the mechanisms of action of procainamide. Circulation, 48, 959–70
Greenspan, K., Steinberg, M., Holland, D. and Freeman, A. R. (1974). Electrophysiological alterations in cardiac dysrhythmias. Antiarrhythmic effects of aprindine. Am. J. Cardiol., 33, 140
Hagemeijer, F. and Hugenholtz, P. G. (1974). Antiarrhythmic efficacy of aprindine in acute myocardial infarction. Am. J. Cardiol., 33, 142
Hai, H. A., Ostrowski, T. L. and Davison, R. (1979). Successful control of resistant ventricular tachycardia with aprindine hydrochloride. Am. J. Cardiol., 43, 358
Han, J., Goel, B. D., Yoon, M. S. and Rodgers, R. (1974). Effect of procainamide and lidocaine on ventricular automaticity and re-entry during acute coronary occlusion. Am. J. Cardiol., 34, 171–8
Hapke, H. J. and Prigge, E. (1976). Pharmakologie von 2’-[Hydroxy–3-(propylamino) propoxy]–3-phenylpropiophenon (Propafenon, SA79)-hydrochlorid. Arzneimittel-Forsch., 26, 1849–57
Harris, A. S. and Kokernot, R. H. (1950). Effects of diphenylhydantoin sodium and phenobarbital sodium upon ectopic ventricular tachycardia in acute myocardial infarction. Am. J. Physiol., 163, 505–16
Harris, A. S., Estandia, A., Ford, T. J. and Tillotson, R. F. (1951). Quinidine lactate and gluconate in the suppression of ectopic ventricular tachycardias associated with myocardial infarction. Control of toxicity by morphine. Circulation, 4, 522–33
Harris, A. S., Estandia, A., Ford, T. J., Smith, H. T., Olsen, R. W. and Tillotson, R. F. (1952). The effects of intravenous procaine and procainamide (Pronestyl) upon ectopic ventricular tachycardia accompanying acute myocardial infarction. Circulation, 5, 551–8
Harrison, D. C. and Alderman, E. L. (1972). The pharmacology and clinical use of lidocaine as an antiarrhythmic drug. Mod. Treat., 9, 139–75
Hauswirth, O. and Singh, B. N. (1978). Ionic mechanisms in heart muscle in relation to the genesis and the pharmacological control of cardiac arrhythmias. Pharmac. Rev., 30, 5–64
Heistracher, P. and Beck, A. (1979). Effects of propafenone on the maximum rate of rise of cardiac action potentials. Arch. Pharmac., 308, Suppl. R37, 039/474
Helfant, R. H., Scherlag, B. J. and Damato, A. N. (1967). The electrophysiological properties of diphenylhydantoin sodium as compared to procainamide in the normal and digitalis-intoxicated heart. Circulation, 36, 108–18
Hill, J. L. and Gettes, L. S. (1980). Effect of acute coronary artery occlusion on local myocardial extracellular K+ activity in swine. Circulation, 61, 768–77
Hodess, A. B., Follansbee, W. P., Spear, J. F. and Moore, E. N. (1979). Electrophysiological effects of a new antiarrhythmic agent, flecainide on the intact canine heart. J. cardiovasc. Pharmac., 1, 427–39
Hoffman, B. F. and Bigger, J. T. (1971). Antiarrhythmic drugs. In Drill’s Pharmacology in Medicine, 4th edn (ed. J. R. Di Palma), McGraw-Hill, New York, pp. 824–52
Hope, R. R., Williams, D. O., El-Sherif, N., Lazzara, R. and Scherlag, B. J. (1974). The efficacy of antiarrhythmic agents during acute myocardial ischemia and the role of heart rate. Circulation, 50, 507–14
Horowitz, J. D., Anavekar, S. N., Morris, P. M., Goble, A. J., Doyle, A. E. and Louis, W. J. (1981). Comparative trial of mexiletine and lignocaine in the treatment of early ventricular tachyarrhythmias after acute myocardial infarction. J. cardiovasc. Pharmac., 3, 409–19
Hurst, V. W., Morris, J. T., Zeft, H. J., Hackel, D. B. and McIntosh, H. D. (1967). Increased survival with prophylactic quinidine after experimental myocardial infarction. Circulation, 36, 294–303
Jackman, W. M., Prystowsky, E. N., Rinkenberger, R. L., Naccarelli, G. V., Heger, J. J. and Zipes, D. P. (1980). Oral encainide increases refractoriness of ventricle, atrium and accessory pathway. Circulation, 62, Suppl. III, 11
Jaillon, P., Kernoff, R. and Winkle, R. (1979). N-Acetylprocainamide and procainamide have different electrophysiologic properties. Am. J. Cardiol., 43, 359
Janse, M. J. (1978). The ideal experimental animal model: the ‘dig’ or the ‘pog’. In Managment of Ventricular Tachycardia — Role of Mexiletine (ed. E. Sandoe, D. G. Julian and J. W. Bell), Excerpta Medica, Amsterdam, p. 38
Jewitt, D. E., Kishon, Y. and Thomas, M. (1968). Lignocaine in the management of arrhythmias after acute myocardial infarction. Lancet, i, 266–70
Johnson, E. A. and McKinnon, M. G. (1957). Differential effect of quinidine and pyrilamine on the myocardial action potential at various rates of stimulation. J. Pharmac. exp. Ther., 120, 460–5
Jones, D. T., Kostuk, W. J. and Gunton, R. W. (1974). Prophylactic quinidine for the prevention of arrhythmias after acute myocardial infarction. Am. J. Cardiol., 33, 655–60
Josephson, M. E., Seides, S. F., Batsford, W. P., Weisfogel, G. M., Akhtar, M., Caracta, A. R., Lau, S. H. and Damato, A. N. (1974). Electrophysiological effects of intramuscular quinidine on the atrioventricular conducting system in man. Am. Heart J., 87, 55–64
Kalusche, D. and Loenne, E. (1978). Die therapie chronischer schwer beeinflussbarer Rhythmusstoerungen mit Propafenon. Z. Kardiol., Suppl. 5, 44
Kane, K. A. (1980). Comparative electrophysiological effects of Org 6001, a new orally active antidysrhythmic agent, and lignocaine on human ventricular muscle. Br. J. Pharmac., 68, 25–31
Kane, K. A. and Winslow, E. (1980). Antidysrhythmic and electrophysiological effects of a new antianginal agent, bepridil. J. cardiovasc. Pharmac, 2, 193–203
Kane, K. A., Lepran, I., McDonald, F. M., Parratt, J. R. and Szekeres, L. (1980). The effects of prolonged oral administration of a new antidysrhythmic drug (Org 6001) on coronary artery ligation dysrhythmias in conscious and anaesthetised rats. J. cardiovasc. Pharmac., 2, 411–23
Kane, K. A., McDonald, F. M. and Parratt, J. R. (1981). What pharmacological properties are necessary for the prevention of early post-infarction ventricular dysrhythmias? Br. J. Pharmac., 72, 512–3P
Kane, K. A., McDonald, F. M., Timmer, C. J., Parratt, J. R. and Vink, J. (1982). Correlation of the antiarrhythmic effects of Org 6001 with plasma and tissue drug concentrations following oral administration in the rat. Br. J. Pharmac., 75, 319–23
Kaplinsky, E., Ogawa, S., Balke, C. W. and Dreifus, L. S. (1979). Two periods of early ventricular arrhythmia in the canine acute myocardial infarction model. Circulation, 60, 397–403
Karlsson, E. (1975). Procainamide and phenytoin: comparative study of their antiarrhythmic effects at apparent therapeutic plasma levels. Br. Heart J., 37, 731–40
Kaverina, N. V., Senova, Z. P., Mitrofanov, V. S. and Runova, M. F. (1972). Pharmacology of ethmosin; a new antiarrhythmic drug. Farmak. Toksikol., 35, 182–5
Kayden, H. J., Brodie, B. B. and Steele, J. M. (1957). Procainamide. Circulation, 15, 118–26
Kesteloot, H. and Stroobandt, R. (1977). Clinical experience with lorcainide (R15889), a new antiarrhythmic drug. Arch. int. Pharmacodyn. Thér., 230, 225–34
Kesteloot, H. and Stroobandt, R. (1979). Clinical experience of encainide (MJ 9067): a new antiarrhythmic drug. Eur. J. clin. Pharmac., 16, 323–6
Kesteloot, H., Van Mieghem, W. and De Geest, H. (1973). Aprindine (AC 1802), a new antiarrhythmic drug. Acta cardiol., 28, 145–65
Kleber, A. G., Janse, M. J., Van Capelle, F. J. L. and Durrer, D. (1978). Mechanism and time course of S-T and T-Q segment changes during acute regional myocardial ischemia in the pig heart determined by extracellular and intracellular recordings. Circulation Res., 42, 603–13
Kojima, M. (1981). Effects of disopyramide on transmembrane action potentials in guinea-pig papillary muscle. Eur. J. Pharmac., 69, 11–24
Kramer, B., Gülker, H. and Meesmann, W. (1981). The effects of lidocaine on the ventricular fibrillation threshold and primary ventricular fibrillation following acute experimental coronary occlusion. Basic Res. Cadiol., 76, 29–43
Kroll, D. A. and Lucchesi, B. R. (1975). Antiarrhythmic and antifibrillatory properties of aprindine. J. Pharmac. exp. Ther., 194, 427–34
Kupersmith, J., Antman, E. M. and Hoffman, B. F. (1975). In vivo electrophysiological effects of lidocaine in canine acute myocardial infarction. Circulation Res., 36, 84–91
Kupersmith, J., Shiang, H., Litwak, R. S. and Herman, M. V. (1976). Electrophysiological effects of verapamil in canine myocardial ischemia. Am. J. Cardiol., 37, 149
Kus, T. and Sasyniuk, B. I. (1976). Effects of disopyramide phosphate on ventricular arrhythmias in experimental myocardial infarction. J. Pharmac. exp. Ther., 196, 665–75
Kus, T. and Sasyniuk, B. I. (1978). The electrophysiological effects of disopyramide phosphate on canine ventricular muscle and Purkinje fibres in normal and low potassium. Can. J. Physiol. Pharmac., 56, 139–49
Lalka, D., Meyer, M. B., Duce, B. R. and Elvin, A. T. (1976). Kinetics of the oral antiarrhythmic lidocaine congener, tocainide. Clin. Pharmac. Ther., 19, 757–66
Lazzara, R., El-Sherif, N. and Scherlag, B. J. (1974). Early and late effects of coronary artery occlusion on canine Purkinje fibres. Circulation Res., 35, 391–9
Lazzara, R., El-Sherif, N., Hope, R. R. and Scherlag, B. J. (1978). Ventricular arrhythmias and electrophysiological consequences of myocardial ischemia and infarction. Circulation Res., 42, 740–9
Levine, H. D. (1932). Effect of quinidine sulphate in inhibiting ventricular fibrillation. Archs int. Med., 49, 808–15
Levites, R. and Anderson, G. J. (1979). Electrophysiological effects of disopyramide phosphate during experimental myocardial ischemia. Am. Heart J., 98, 339–44
Le Winter, M. M., Engler, R. L. and Karliner, J. S. (1980). Tocainamide therapy for treatment of ventricular arrhythmias: assessment with ambulatory electrocardiographic monitoring and treadmill exersie. Am. J. Cardiol., 45, 1045–52
Lown, B. and Wolf, M. (1971). Approaches to sudden death from coronary heart disease. Circulation, 44, 130–42
McDevitt, D. G., Nies, A. S., Wilkinson, G. R., Smith, R. F., Woosley, R. L. and Oates, J. A. (1976). Antiarrhythmic effects of a lidocaine congener, tocainide, 2-amino–2’, 6’-propionoxylidide, in man. Clin. Pharmac. Ther., 19, 396–404
McDonald, F. M. (1980). Experimental models for the production of cardiac dysrhythmias and for the assessment of activity of antidysrhythmic drugs. PhD thesis, University of Strathclyde, Glasgow
Madan, B. R., Arora, R. B. and Kapila, K. (1960). Anticonvulsant, antiveratrinic and antiarrhythmic actions of Acorus calamus Linn. An Indian indigenous drug. Archs int. Pharmacodyn. Thér., 124, 201–11
Malini, P. L., Ambrosioni, E., Bracchetti, D. and Magnani, B. (1979). Evaluation of clinical efficacy and plasma levels of aprindine. Int. J. Clin. Pharmac. Biopharm., 17, 396–403
Manz, M., Steinbeck, G. and Lüderitz, B. (1978). Wirkung von Lorcainid (R 15889) auf Sinusknotenfunktion und intrakardiale Erregunsleitung. Herbsttagung dt. Ges. Kreislaufforsch., Abstract 78
Mark, L. C., Kayden, H. J., Steel, J. M., Dooper, J. R., Berlin, I., Rovenstine, E. A. and Brodie, B. B. (1951). The physiological disposition and cardiac effects of procainamide. J. Pharmac. exp. Ther., 102, 5–17
Marshall, R. J. and Muir, A. W. (1981). The antiarrhythmic, haemodynamic and metabolic effects of a new antianginal agent, bepridil, in the early stages of canine acute myocardial infarction. Br. J. Pharmac., 72, 114–5P
Marshall, R. J. and Parratt, J. R. (1975). Antiarrhythmic, haemodynamic and metabolic effects of 3α-amino–5α-androstan–2β-ol–17-one hydrochloride in greyhounds following acute coronary artery ligation. Br. J. Pharmac., 55, 359–68
Marshall, R. J. and Parratt, J. R. (1977a). The haemodynamic and metabolic effects of MG8926, a prospective antidysrhythmic and anti-anginal agent. Br. J. Pharmac., 59, 311–22
Marshall, R. J. and Parratt, J. R. (1977b). The antidysrhythmic aminosteroid, Org 6001, reduces the ST-segment elevation produced by coronary occlusion in the dog. Br. J. Pharmac., 61, 315–7
Marshall, R. J. and Parratt, J. R. (1979). The effects of disopyramide phosphate on early post-coronary artery ligation dysrhythmias and on epicardial ST-segment elevation in anaesthetised dogs. Br. J. Pharmac., 66, 241–50
Marshall, R. J. and Parratt, J. R. (1980a). The early consequences of myocardial ischaemia and their modification. J. Physiol., Paris, 76, 699–715
Marshall, R. J. and Parratt, J. R. (1980b). Prophylactic lignocaine and early postcoronary artery occlusion dysrhythmias in anaesthetised greyhounds. Br. J. Pharmac., 71, 597–600
Marshall, R. J., Muir, A. W. and Winslow, E. (1981). A comparison of the intensity and duration of the antidysrhythmic effect of mexiletine and Org 6001 in anaesthetised rats. Br. J. Pharmac., 74, 381–8
Mason, J. W. and Peters, F. A. (1980). Antiarrhythmic efficacy of encainide in patients with refractory recurrent ventricular tachycardia. Circulation, 62, Suppl. III, 153
Meesmann, W., Gülker, H., Kramer, B. and Stephan, K. (1976). Time course of changes in ventricular fibrillation threshold in myocardial infarction: characteristics of acute and slow occlusion with respect to the collateral vessels of the heart. Cardiovasc. Res., 10, 466–73
Meinertz, T., Kaspar, W., Kersting, F., Just, H., Bechtold, H. and Jahnchen, E. (1979). Lorcainide. II. Plasma concentration-effect relationship. Clin. Pharmac. Ther., 26, 187–95
Meinertz, T., Kasper, W., Kersting, F., Bechtold, H., Just, H. and Jahnchen, E. (1980a). Antiarrhythmic effect of lorcainide during chronic treatment. Arzeimittel-Forsch., 30, 1593–5
Meinertz, T., Kersting, F., Kasper, W., Just, H., Bechtold, H. and Jahnchen, E. (1980b). Haemodynamic effects of a single intravenous dose of lorcainide in patients with heart disease. Eur. J. clin. Pharmac., 18, 461–5
Merx, W., Henning, B., Franken, G. and Effert, S. (1978). Mexiletine in acute myocardial infarction. In Management of Ventricular Tachycardia — Role of Mexiletine (ed. E. Sandoe, D. G. Julian and J. W. Bell), Excerpta Medica, Amsterdam, pp. 472–8
Meyer, E. G., Keller, K., Beck, O. A. and Hochrein, H. (1978). Antiarrhythmische Wirksamkeit bon propafenon in Abhaengigkeit von Serumkonzentration unde Erregungsleitungshemmung. Z. Kardiol., 67, 352–6
Mirro, M. J., Watanabe, A. M. and Baily, J. C. (1979). Anticholinergic effects of quinidine and disopyramide on canine cardiac Purkinje fibres. Clin. Res., 27, 189A
Mokler, C. M. and Van Arman, C. G. (1962). Pharmacology of a new antiarrhythmic agent α-diisopropylamine-α-phenyl-α-(2-pyridyl)butyramide (SC-7031). J. Pharmac. exp. Ther., 136, 114–24
Morganroth, J., Pearlman, A. S., Dunkman, W. B., Horowitz, L. N., Josephson, M. E. and Michelson, E. L. (1979). Ethmosine — a new antiarrhythmic agent developed in the USSR. Efficacy and tolerance. Am. Heart. J., 98, 621–8
Morganroth, J., Dreifus, L. S., Michelson, E. L. and Sawain, H. S. (1980). Efficacy and tolerance of lorcainide. Circulation, 62, 111–80
Myburgh, D. P., Goldman, A. P. and Schamroth, J. M. (1980). Lorcainide — an antiarrhythmic agent for ventricular arrhythmias. S. Afr. med. J., 57, 236–9
Nakaya, H., Hattori, Y. and Kanno, M. (1980). Effects of calcium antagonists and lidocaine on conduction delay induced by acute myocardial ischaemia in dogs. Jap. J. Pharmac., 30, 587–97
Nattel, S., Pederson, D. H. and Zipes, D. P. (1979). Regional myocardial aprindine concentration and effects on arrhythmia after coronary occlusion. Am. J. Cardiol., 43, 358
Nattel, S., Elharrar, V., Zipes, D. P. and Bailey, J. C. (1981). pH-dependent electrophysiological effects of quinidine and lidocaine on canine cardiac Purkinje fibres. Circulation Res., 48, 55–61
Neuss, H. and Buss, J. (1978). Wirkungsspektrum neuer Antiarrhythmika. Internist, 19, 234–40
Ogawa, S., Kaplinsky, E., Balke, C. W. and Dreifus, L. S. (1979). Evidence of two periods of early ventricular arrhythmia following acute myocardial infarction. Am. J. Cardiol., 43, 371
Okuma, K., Sugiyama, S., Wada, M., Sugenoya, J., Niimi, N., Oguri, H., Toyama, J. and Yamada, K. (1976). Experimental studies on the antiarrhythmic action of a lidocaine analog. Cardiology, 61, 289–97
Opie, L. H. (1980). Drugs and the heart: IV. Antiarrhythmic agents. Lancet, i, 861–8
Parratt, J. R. (1979). The search for prophylactic antidysrhythmic drugs — the place of aminosteroids. Progr. Pharmac., 2, 85–94
Patterson, E., Gibson, J. J. and Lucchesi, B. R. (1980). Electrophysiological effects of disopyramide phosphate on re-entrant ventricular arrhythmia in conscious dogs after myocardial infarction. Am. J. Cardiol., 46, 792–9
Pentecost, B. L., De Giovanni, J. V., Lamb, P., Cadigan, P. J., Everny, K. L. and Flint, E. J. (1981). Reappraisal of lignocaine therapy in management of myocardial infarction. Br. Heart J., 45, 42–7
Pozenel, H. (1977). Haemodynamic studies on mexiletine, a new antiarrhythmic agent. Postgrad. med. J., 53, 78–80
Prinzmetal, M., Toyashima, H., Ekmekci, A. and Nagaya, T. (1962). Angina pectoris. VI. Nature of ST-segment elevation and other ECG changes in acute severe ischaemia. Clin. Sci., 23, 489–514
Probst, P. and Pachinger, O. (1976). Einfluesse von Propafenone auf die Haemodynamik des linken Ventrikels und die atrioventrikulaere Ueberleitung unter besonderer Beruecksichtigung des WPW-Syndroms. Z. Kardiol., 65, 212–24
Reddy, C. P., Damato, A. N., Akhtar, M., Dhatt, M. S., Gomes, J. A. C. and Calon, A. H. (1977). Effect of procainamide on re-entry within the His-Purkinje system in man. Am. J. Cardiol., 40, 957–64
Reynolds, R. D. and Kamath, B. L. (1979). N-Acetylprocainamide and ischaemiainduced ventricular fibrillation in the dog. Eur. J. Pharmac., 59, 115–9
Ribner, H. S., Isaacs, E. S. and Frishman, W. H. (1979). Lidocaine prophylaxis against ventricular fibrillation in acute myocardial infarction. Progr. cardiovasc. Dis., 21, 287–313
Ro, J., Gillon, J. and Kupersmith, J. (1979). Electrophysiologic effects of encainide following acute coronary occlusion in dogs. Pharmacologist, 21, 200
Roden, D. M., Reele, S. B., Higgins, S. B., Carr, R. K., Smith, R. F., Oates, J. A. and Woosley, R. L. (1980a). Tocainide therapy for refractory ventricular arrhythmias. Am. Heart J., 101, 15–22
Roden, D. M., Reele, S. B., Higgins, S. B., Mayol, R. F., Gammans, R. E., Oates, J. A. and Woosley, R. L. (1980b). Total suppression of ventricular arrhythmias by encainide. Pharmacokinetic and electrocardiographic characteristics. New Engl. J. Med., 302, 877–82
Ronfeld, R. A. M., Wolshin, E. M. and Block, A. J. (1980). Tocainamide and metabolities: human pharmacokinetics and animal pharmacology. Clin. Pharmac. Ther., 27, 282
Rosen, M. R. and Hoffman, B. F. (1973). Mechanisms of action of antiarrhythmic drugs. Circulation Res., 32, 1–8
Rosen, M. R., Merker, C., Gelband, H. and Hoffman, B. F. (1973). Effects of procainamide on the electrophysiologic properties of the canine ventricular conducting system. J. Pharmac. exp. Ther., 185, 438–46
Rosen, M. R., Hoffman, B. F. and Wit, A. L. (1975). Electrophysiology and pharmacology of cardiac arrhythmias. V. Cardiac antiarrhythmic effects of lidocaine. Am. Heart J., 89, 526–36
Ruffy, R., Rozenshtraukh, L., Elharrar, V. and Zipes, D. P. (1977). Cardiac electrophysiologic properties of ethmozine. Clin. Res., 25, 557A
Russell, D. C., Smith, H. J. and Oliver, M. F. (1979). Transmembrane potential changes and ventricular fibrillation during repetitive myocardial ischaemia in the dog. Br. Heart J., 42, 88–96
Ryan, W. R. and Karliner, J. S. (1979). Effects of tocainide on left ventricular performance at rest and during acute alterations in heart rate and systemic arterial pressure. An echocardiographic study. Br. Heart J., 41, 175–81
Salako, L. A., Vaughan Williams, E. M. and Wittig, J. H. (1976). Investigations to characterise a new antiarrhythmic drug, Org 6001, including a simple test for calcium antagonism. Br. J. Pharmac., 57, 251–62
Sasyniuk, B. I. and Kus, T. (1974). Comparison of the effects of lidocaine on electrophysiological properties of normal Purkinje fibres and those surviving acute myocardial infarction. Fedn Proc. Fedn Am. Socs exp. Biol., 33, 476
Schaub, R. G., Stewart, G., Strong, M., Ruotola, R. and Lemole, G. (1977). Reduction of ischemic myocardial damage in the dog by lignocaine infusion. Am. J. Path., 87, 399–414
Scherlag, B. J., Herfant, R. H., Haft, J. J. and Damato, A. N. (1970). Electrophysiology underlying ventricular arrhythmias due to coronary ligation. Am. J. Physiol., 219, 1665–71
Scherlag, B. J., Harrison, L. A., Kabell, G., Brachmann, J., Harrison, L. H. and Lazzara, R. (1980). Lidocaine unmasks ventricular arrhythmias in chronic myocardial infarction. Circulation, 62, 111–73
Schmid, J. R., Seeback, B. D., Hennie, C. L., Banitt, E. H. and Kuam, D. C. (1975). Some antiarrhythmic actions of a new compound, R-818, in dogs and mice. Fedn Proc. Fedn Am. Socs exp. Biol., 34, 775
Seipel, L., Breithardt, G., Both, A. and Loogen, F. (1974). Messung der ‘sinuatrialen Leitungszeit’ mittels verzeitiger Vorhofstimulation beim Menschen. Dt. med. Wschr., 99, 1895–900
Seipel, L., Breithardt, G. and Both, A. (1975). Elektrophysiologische Effekte der Antiarrhythmika Disopyramid und Propafenon auf das menschliche Reizleitungssystem. Z. Kardiol., 64, 731–40
Seipel, L., Abendroth, R. R. and Breithardt, G. (1980). Electrophysiological effects of flecainide R-818 in man. Circulation, 62, 153
Sekiya, A. and Vaughan Williams, E. M. (1963). A comparison of the antifibrillatory actions and effects on intracellular cardiac potentials of pronethalol, disopyramide and quinidine. Br. J. Pharmac., 21, 473–81
Shenoy, P. N., Ogawa, S., Osmick, M. J. and Dreifus, L. S. (1977). Electrophysiologic effects of ethmozin (EN313), a new antiarrhythmic agent. Clin. Res., 25, 276A
Singer, D. H., Lazzara, R. and Hoffman, B. F. (1967). Interrelationships between automaticity and conduction in Purkinje fibres. Circulation Res., 21, 537–58
Singh, B. N. (1977). Side effects of antiarrhythmic drugs. Pharmac. Ther. C, 2, 151–66
Singh, B. N. and Vaughan Williams, E. M. (1970). The effect of amiodarone, a new anti-anginal drug, on cardiac muscle. Br. J. Pharmac., 39, 657–68
Singh, B. N. and Vaughan Williams, E. M. (1972). Investigations of the mode of action of a new antidysrhythmic drug Kö 1173. Br. J. Pharmac., 44, 1–9
Somani, P. (1980a). Clinical pharmacology of lorcainide, a new antiarrhythmic drug in patients with cardiac dysrhythmias. Clin. Res., 28, 590A
Somani, P. (1980b). Antiarrhythmic effects of flecainide. Clin. Pharmac. Ther., 27, 464–70
Sonnhag, C. (1980). Efficacy and tolerance of tocainide during acute and long-term treatment of chronic ventricular arrhythmias. Eur. J. clin. Pharmac., 18, 301–10
Southworth, J. L., McKusick, V. A., Peine, E. L. and Rawson, F. L. (1950). Ventricular fibrillation precipitated by cardiac catheterization: complete recovery of patient after 45 mins. J. Am. med. Assoc., 143, 717–20
Stephenson, S. E., Cole, R. K., Parrish, T. F., Bauer, F. M., Johnson, I. T., Kochtitzky, M., Anderson, J. S., Hibbitt, L. L., McCarty, J. E., Young, E. R., Wilson, J. R., Meiers, H. N., Meador, C. K., Ball, O. T. and McNeely, G. R. (1960). Ventricular fibrillation during and after coronary artery occlusion. Incidence and protection afforded by various drugs. Am. J. Cardiol., 5, 77–87
Stern, H., Yelnosky, J. and Clark, B. B. (1952). Action of procainamide on ventricular tachycardia produced by coronary artery ligation. Fedn Proc. Fedn. Am. Socs exp. Biol., 11, 393
Stone, N., Klein, M. D. and Lown, B. (1971). Diphenylhydantoin in the prevention of recurring ventricular tachycardia. Circulation, 43, 420–9
Talbot, R. G., Clark, R. A., Nimmo, J., Neilson, J. M. M., Julian, D. G. and Prescott, L. F. (1973). Treatment of ventricular arrhythmias with mexiletine (Kö-1173). Lancet, ii, 399–404
Ueda, M., Kimoto, S., Matsuda, S., Kawakami, M., Morishige, E., Matsumura, S. and Takeda, H. (1975). Antiarrhythmic effect of aprindine on several types of ventricular arrhythmias. Jap. J. Pharmac., 25, 549–61
Vargaftig, B. B., Sugrue, M. F., Buckett, W. R. and Van Riezen, H. (1975). Org 6001 (3α-amino–5α-androstan–2β-ol–17-one hydrochloride) a steroidal antiarrhythmic agent. J. Pharm. Pharmac., 27, 697–9
Vaughan Williams, E. M. (1958). The mode of action of quinidine in isolated rabbit atria interpreted from intracellular records. Br. J. Pharmac. Chemother., 13, 276–87
Vaughan Williams, E. M. (1970). Classifiction of antiarrhythmic drugs. In Symposium on Cardiac Arrhythmias (ed. E. Sandoe, E. G. Flensted-Jensen and K. H. Olesen), Astra, Södertälje, pp. 449–72
Vaughan Williams, E. M. (1977). Mexiletine in isolated tissue models. Postgrad. med. J., 53, 30–4
Vaughan Williams, E. M. (1978). Some factors that influence the activity of antiarrhythmic drugs. Br. Heart J., 40, 52–61
Vaughan Williams, E. M. (1979). Characterisation of new antiarrhythmic drugs. Progr. Pharmac., 2, 13–24
Vaughan Williams, E. M. (1980). Antiarrhythmic Action and the Puzzle of Perhexilene, Academic Press, London
Venkataramanan, R. and Axelson, J. E. (1980). Dose-dependent pharmacokinetics of tocainide in the rat. J. Pharmac. exp. Ther., 215, 231–4
Verdonck, F., Vereecke, J. and Vleugels, A. (1974). Electrophysiological effects of aprindine on isolated heart preparation. Eur. J. Pharmac., 26, 338–47
Verdouw, P. D., Remme, W. J. and Hugenholtz, P. G. (1977). Cardiovascular and antiarrhythmic effects of aprindine (AC 1802) during partial occlusion of a coronary artery in the pig. Cardiovasc. Res., 11, 317–23
Verdouw, P. D., Schamhardt, H. C., Remme, W. J. and De Jong, J. W. (1978). Antiarrhythmic, metabolic and haemodynamic effects of Org 6001 (3α-amino–5α-androstan–2β-ol–17-one hydrochloride) after coronary flow reduction in pigs J. Pharmac. exp. Ther., 204, 634–44
Verdouw, P. D., Deckers, J. W. and Conard, G. J. (1979). Antiarrhythmic and haemodynamic actions of flecainide acetate (R-818) in the ischaemic porcine heart. J. cardiovasc. Pharmac., 1, 473–86
Vikhliaev, Y. I., Kaverina, N. V., Senova, Z. P. and Vl ’Yanova Ov (1971). Relationship between structure and antiarrhythmic activity in the 10-acyl derivatives of 2-trifluoro-substituted phenothiazine and phenothiazine–2-carbamates. Farmak. Toksikol., 34, 163–7
Vogel, S., Crampton, R. and Sperelakis, N. (1979). Selective blockade of myocardial slow channels by bepridil (CERM–1978). J. Pharmac. exp. Ther., 210, 378–85
Wald, R. W., Waxman, M. B. and Downar, E. (1980). The effect of antiarrhythmic drugs on depressed conduction and unidirectional block in sheep Purkinje fibres. Circulation Res., 46, 612–9
Wallace, A. G., Cline, R. E., Sealy, W. G. and Troyer, W. J. (1966). Electrophysiological effects of quinidine. Circulation Res., 19, 960–9
Wang, T. and Woosley, R. L. (1980). Contribution of a metabolite to the ECG and antiarrhythmic actions of encainide. Circulation, 62, Suppl. III, 141
Wasenmiller, J. E. and Aronow, W. S. (1980). Effect of tocainide and quinidine on premature ventricular contractions. Clin. Pharmac. Ther., 28, 431–5
Watanabe, Y., Dreifus, L. S. and Likoff, W. (1963). Electrophysiologic antagonism and synergism of potassium and antiarrhythmic agents. Am. J. Cardiol., 12, 702–10
Weidmann, S. (1955). Effect of calcium ions and local anaesthetics on electrical properties of Purkinje fibres. J. Physiol., Lond., 129, 568–82
Weisse, A. B., Moschos, C. B., Passannante, A. J., Khan, M. I. and Regan, T. J. (1971). Relative effectiveness of three antiarrhythmic agents in the treatment of ventricular arrhythmias in experimental acute myocardial ischemia. Am. Heart J., 81, 503–10
Weld F. M. and Bigger, J. T. (1976). The effect of lidocaine on diastolic transmembrane currents determining pacemaker depolarization in cardiac Purkinje fibres. Circulation Res., 38, 203–8
Weld, F. M., Bigger, J. R., Swistel, D., Bordiuk, J. and Lau, Y. H. (1979). Electrophysiological effects of mexiletine (Kö 1173) on ovine cardiac Purkinje fibres. J. Pharmacol. exp. Ther., 210, 222–8
Wenckebach, K. F. (1914). In Die Unregalmassige Herstatigkeit Undre Ihre Bedeutung (ed. W. Engellman), Leipzig, p. 124
Wenger, T. L., Masterton, C. E., Abou-Donia, M. B., Lee, K. L., Bache, R. J. and Strauss, H. C. (1978). Relationship between regional myocardial procainamide concentration and regional myocardial blood flow during ischemia in the dog. Circulation Res., 42, 846–51
West, T. C. and Amory, D. N. (1960). Single fibre recording of the effect of quinidine at atrial and pacemaker sites in the isolated right atrium of the rabbit. J. Pharmacol. exp. Ther., 130, 183–93
Williams, D. P., Scherlag, B. J., Hope, R. R., El-Sherif, N. and Lazzara, R. (1974). The pathophysiology of malignant ventricular arrhythmias during acute myocardial ischemia. Circulation, 50, 1163–72
Winbury, M. M. and Hemmer, M. L. (1955). Action of quinidine, procaineamide and other compounds on experimental atrial and ventricular arrhythmias in the dog. J. Pharmacol. exp. Ther., 113, 402–13
Winslow, E. (1980). Evaluation of antagonism of aconitine-induced dysrhythmias in mice as a method of detecting and assessing antidysrhythmic activity. Br. J. Pharmac., 71, 615–22
Wit, A. L. and Bigger, J. T. (1975). Possible electrophysiological mechanisms for lethal arrhythmias accompanying myocardial ischemia and infarction. Circulation, 51, Suppl. 3, 96–115
Wit, A. L., Rosen, M. R. and Hoffman, B. F. (1974). Electrophysiology and pharmacology of cardiac arrhythmias. II. Relationship of normal and abnormal electrical activity of cardiac fibres to the genesis of arrhythmias. A. Automaticity. Am. Heart J., 86, 515–24
Wit, A. L., Rosen, M. R. and Hoffman, B. F. (1975). Electrophysiology and pharmacology of cardiac arrhythmias. VIII. Cardiac effects of diphenylhydantoin. Am. Heart J., 90, 397–404
Wittig, J. H., Harrison, L. A. and Wallace, A. G. (1973). Electrophysiological effects of lidocaine on distal Purkinje fibres of canine heart. Am. Heart J., 86, 69–78
Woosley, R. L., McDevitt, D. G., Nies, A. S., Smith, R. F., Wilkinson, G. R. and Oates, J. A. (1977). Suppression of ventricular ectopic depolarisations by tocainide. Circulation, 56, 980–4
Yamada, K., Ikeda, N., Goto, J., Okuma, K., Iwamura, N., Toyoshima, H., Toyama, J. and Hanimi, K. (1978). Electrophysiological action of mexiletine on dog Purkinje and papillary muscle fibres studies in both in vitro and in situ experiments. In Management of Ventricular Tachycardia — Role of Mexiletine (ed. E. Sandoe, D. G. Julian and J. W. Bell), Excerpta Medica, Amsterdam, pp. 210–6
Yamaguchi, I., Singh, B. N. and Mandel, W. J. (1978). Electrophysiological effects of mexiletine on isolated cardiac tissue. In Management of Ventricular Tachycardia — Role of Mexiletine (ed. E. Sandoe, D. G. Julian and J. W. Bell), Excerpta Medica, Amsterdam, pp. 197–209
Yeh, B. K., Sung, P. K. and Scherlag, B. J. (1973). Effects of disopyramide on electrophysiological and mechanical properties of the heart. J. pharm. Sci., 62, 1924–9
Yu, P. N. (1979). Disopyramide phosphate (Norpace). A new antiarrhythmic drug. Circulation, 59, 236–7
Zipes, D. P. and Troup, P. J. (1978). New antiarrhythmic agents. Am. J. Cardiol., 41, 1005–24
Zipes, D. P., Elharrar, V., Noble, R. J., Gaum, W. E., Troup, P. J. and Fasola, A. (1977a). Effects of various drugs on ventricular conduction delay and ventricular arrhythmias during myocardial ischaemia in the dog. In Re-entrant Arrhythmias. Mechanisms and Treatment (ed. H. E. Kulbertus), Medical and Technical Press, Lancaster, pp. 312–26
Zipes, D. P., Gaum, W. E., Foster, P. R., Rosen, K. M., Wu, D., Amatyleo, F. and Noble, R. J. (1977b). Aprindine for treatment of supraventricular tachycardias: with particular application of Wolff-Parkinson-White syndrome. Am. J. Cardiol., 40, 586–96
Editor information
Editors and Affiliations
Copyright information
© 1982 The contributors
About this chapter
Cite this chapter
Marshall, R.J., Winslow, E. (1982). The Effects of Sodium Channel Inhibitors on Early Arrhythmias Associated with Acute Myocardial Ischaemia. In: Parratt, J.R. (eds) Early Arrhythmias Resulting from Myocardial Ischaemia. Palgrave Macmillan, London. https://doi.org/10.1007/978-1-349-06260-7_15
Download citation
DOI: https://doi.org/10.1007/978-1-349-06260-7_15
Publisher Name: Palgrave Macmillan, London
Print ISBN: 978-1-349-06262-1
Online ISBN: 978-1-349-06260-7
eBook Packages: MedicineMedicine (R0)